The serine protease inhibitors TLCK and TPCK react with the RB-binding core of HPV-18 E7 protein and abolish its RB-binding capability

Virology

Volumn 217, Issue 2, 1996, Pages 542-553

  Stöppler, Hubert ^a   Stöppler, Melissa Conrad ^a   Adduci, Alexander ^a   Koval, Debra ^a   Schlegel, Richard ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERINE PROTEINASE INHIBITOR; TOSYLLYSYL CHLOROMETHYL KETONE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE;

ARTICLE; CONTROLLED STUDY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; VIRUS CELL INTERACTION; WART VIRUS;

EID: 0343462224     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0149     Document Type: Article

References (56)

1. Banks, L., Edmonds, C., and Vousden, K. H. (1990). Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene 5, 1383-1389.
2. Barbosa, M. S., and Schlegel, R. (1989). The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 4, 1529-1532.
3. Barbosa, M. S., Edmonds, C., Fisher, C., Schiller, J. T., Lowy, D. R., and Vousden, K. H. (1990). The region of the HPV E7 oncoprotein homologous to adenovirus E1a and SV40 large T antigen contains separate domains for Fb binding and casein kinase II phosphorylation. EMBO J. 9, 153-160.
4. Bedell, M., Jones, K., and Laimins, L. (1987). The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and Rat-1 cells. J. Virol. 61, 3635-3640.
5. Bedell, M. A., Jones, K. H., Grossman, S. R., and Laimins, L. A. (1989). Identification of human papillomavirus type 18 transforming genes in immortalized and primary cells. J. Virol. 63, 1247-1255.
6. Chesters, P. M., and McCance, D. J. (1989). Human papillomavirus types 6 and 16 in cooperation with Ha-ras transform secondary rat embryo fibroblasts. J. Gen. Virol. 70, 353-365.
7. Dalton, S. (1992). Cell cycle regulation of the human cdc2 gene. EMBO J. 11, 1797-1804.
8. Davies, R., Hicks, R., Crook, T., Morris, J., and Vousden, K. (1993). Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J. Virol. 67, 2521-2528.
9. DeCaprio, J. A., Ludlow, J. W., Figge, J., Shew, J.-Y., Huang, C.-M., Lee, W.-H., Marsilio, E., Paucha, E., and Livingston, D. W. (1988). SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54, 275-283.
10. de Villiers, E.-M. (1989). Heterogeneity of the human papillomavirus group. J. Virol. 63, 4898-4903.
11. Dürst, M., Dzarlieva-Petrusevska, R. T., Boukamp, P., Fusenig, N. E., and Gissmann, L. (1987). Molecular and cytogenetic analysis of immortalized human keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1, 251-256.
12. Dyson, N., Guida, P., Monger, K., and Harlow, E. (1992). Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66, 6893-6902.
13. Dyson, N., Howley, P. M., Münger, K., and Harlow, E. (1989). The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-937.
14. Fisher, R. J., Koizumi, S., Kondoh, A., Mariano, J. M., Mavrothalassitis, G., Bhat, N. K., and Papas, T. S. (1992). Human ETS1 oncoprotein. Purification, isoforms, -SH modification, and DNAsequence-specific binding. J. Biol. Chem. 267, 17957-17965.
15. Gage, J. R., Meyers, C., and Wettstein, F. O. (1990). The E7 Proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol. 64, 723-730.
16. Green, S., Issemann, I., and Sheer, E. (1988). A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res. 16, 369.
17. Halbert, C. L., Demers, G. W., and Galloway, D. A. (1991). The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65, 473-478.
18. Halbert, C. L., Demers, G. W., and Galloway, D. A. (1992). The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 66, 2125-2134.
19. Heck, D. V., Yee, C. L., Howley, P. M., and Münger, K. (1992). Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. USA 89, 4442-4446.
20. Hedvat, C. V., and Irving, S. G. (1995). The isolation and characterization of MINOR, a novel mitogen-inducible nuclear orphan receptor. Mol. Endocr. 9, 1692-1700.
21. Imai, Y., Matsushima, Y., Sugimura, T., and Terada, M. (1991). Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. J. Virol. 65, 4966-4972.
22. Jewers, R. J., Hildebrandt, P., Ludlow, J. W., Kell, B., and McCance, D. J. (1992). Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J. Virol. 66, 1329-1335.
23. Kanda, T., Watanabe, S., and Yoshike, K. (1987). Human papilomavirus type 16 transformation of rat 3Y1 cells. Jpn. J. Cancer Res. (Gann) 78, 103-108.
24. Kanda, T., Watanabe, S., and Yoshiike, K (1988). Immortalization of primary rat cells by human papillomavirus type 16 subgenomic fragments controlled by the SV40 promoter. Virology 165, 321-325.
25. Kinzel, V., and König, N. (1980). Interaction of protease inhibitors with the catalytic subunit of cAMP-dependent kinase. Biochem. Biophys. Res. Commun. 93, 349-353.
26. Kozak, M. (1987). At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mo.. Biol. 196, 947-950.
27. Kupfer, A., Gani, V., Jiménez, J. S., and Shaltiel, S. (1979). Affinity labeling of the catalytic subunit of cyclic AMP-dependent protein kinase by N-α-tosyl-L-lysine chloromethyl ketone. Proc. Natl. Acad. Sci. USA 76, 3073-3077.
28. Lalou, C. I., and Lederer, F. (1993). Affinity labeling of bovine brain protein kinase C by tosyl lysyl chloromethane: A kinetic study. Biochimie 75, 443-450.
29. Lam, E. W.-F., Morris, J. D. H., Davies, R., Crook, T., Watson, R. J., and Vousden, K. H. (1994). HPV16 E7 oncoprotein deregulates B-myb expression: Correlation with targeting of p107/E2F complexes. EMBO J. 13, 871-878.
30. Lukas, J., Müller, H., Bratkova, J., Spitkovsky, D., Kjerulff, A. A., Jansen-Dürr, P., Strauss, M., and Bartek, J. (1994). DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J. Cell Biol. 125, 625-638.
31. McCance, D. J., Kopan, R., Fuchs, E., and Laimins, L. A. (1988). Human papillomavirus type 16 DNA alters human cell differentiation in vitro. Proc. Natl. Acad. Sci. USA 85, 7169-7173.
32. McIntyre, M. C., Frattini, M. G., Grossman, S. R., and Laimins, L. A. (1993). Human papillomavirus type 18 E7 protein requires intact CysX-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J. Virol. 67, 3142-3150.
33. Moran, E., and Mathews, M. B. (1987). Multiple functional domains in the adenovirus E1A gene. Cell 48, 177-178.
34. Mudryi, M., Hiebert, S. W., and Nevins, J. R. (1990). A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway. EMBO J. 9, 2179-2184.
35. Münger, K., Phelps, W. C., Bubb, V., Howley, P. H., and Schlegel, R. (1989). The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63, 4417-4421.
36. Phelps, W. C., Yee, C. L., Munger, K., and Howley, P. M. (1988). The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53, 539-547.
37. Pirisi, L., Yasumoto, S., Feller, M., Doniger, J., and DiPaolo, J. A. (1987). Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J. Virol. 61, 1061-1066.
38. Sang, B. C., and Barbosa, M. S. (1992). Single amino acid substitutions in "low-risk" human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the "high-risk" HPV E7 oncoproteins. Proc. Natl. Acad. Sci. USA 89, 8063-8067.
39. Scheffner, M., Huibregste, J. M., and Howley, P. M. (1994). Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. USA 91, 8797-8801.
40. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
41. Schlegel, R., Phelps, W. C., Zhang, Y. L., and Barbosa, M. (1988). Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J. 7, 3181-3187.
42. Schoellmann, G., and Shaw, E. (1963). Direct evidence for the presence of histidine in the active center of chymotrypsin. Biochemistry 2, 252-255.
43. Shaw, E. (1970). Selective chemical modification of proteins. Physiol. Rev. 50, 244-296.
44. Solomon, D. H., O'Brian, C. A., and Weinstein, I. B. (1985). N-α-tosyl-L-lysine chloromethyl ketone and N-α-tosyl-L-phenylalanine chloromethyl ketone inhibit protein kinase C. FEBS Lett. 190, 342-344.
45. Stevenson, K. J. (1974). The selective isolation of an active-site histidine peptide from chymotrypsin-a by diagonal peptide 'mapping.' Biochem. J. 139, 215-220.
46. Stirdivant, S. M., Huber, H. E., Patrick, D. R., Defeo, J. D., McAvoy, E. M., Garsky, V. M., Oliff, A., and Heimbrook, D. C. (1992). Human papillomavirus type 16 E7 protein inhibits DNA binding by the retinoblastoma gene product. Mol. Cell. Biol. 12, 1905-1914.
47. Storey, A., Pim, D., Murray, A., Osborn, K., Banks, L., and Crawford, L. (1988). Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J. 7, 1815-1820.
48. Tommasino, M., Adamczewski, J. P., Carlotti, F., Barth, C. F., Manetti, R., Contorni, M., Cavalieri, F., Hunt, T., and Crawford, L. (1993). HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 8, 195-202.
49. Villa, L. L., and Schlegel, R. (1991). Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virology 181, 374-377.
50. Vousden, K. H., Doniger, J., DiPaolo, J. A., and Lowy, D. R. (1988). The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res. 3, 167-175.
51. Watanabe, S., Kanda, T., Sato, H., Furuno, A., and Yoshiike, K. (1990). Mutational analysis of human papillomavirus type 16 E7 functions. J. Virol. 64, 207-214.
52. Werness, B. A., Levine, A. J., and Howley, P. M. (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248, 76-79.
53. Xiong, Y., Zhang, H., and Beach, D. (1993). Subunit rearrangement of cyclin-dependent kinases is associate with cellular transformation. Genes Dev. 7, 1572-1583.
54. Yasumoto, S., Burkhardt, A., Doniger, J., and DiPaolo, J. (1986). Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J. Virol. 57, 572-577.
55. Yuspa, S. H., and Harris, C. C. (1974). Altered differentiation of mouse epidermal cells treated with retinyl acetate in vitro. Exp. Cell Res. 86, 95-105.
56. zur Hausen, H. (1991). Human papillomaviruses in the pathogenesis of human anogenital cancer. Virology 184, 9-13.